CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
天然且革命性的肿瘤特异性 T 细胞治疗
英文原题：Natural and revolutionary tumor-specific T-cell therapy.
查看英文原题
Natural and revolutionary tumor-specific T-cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
最近，FDA进行了一项风险调查，并对所有靶向BCMA和CD19的CAR-T 细胞疗法标注了黑框警告，那么这是否意味着公众必须为了接受细胞疗法而承担继发性癌症的风险？在此，无需慢病毒和专业的抗原呈递细胞应用，仅通过将MHC+癌细胞与Na ve-T细胞在CD28共刺激信号下共培养，就成功开发了一种新型的肿瘤特异性T细胞疗法。这些肿瘤特异性T细胞可以通过细胞大小进行分离，并能从外周血中大量产生，且在体外试验中会自发攻击携带相同肿瘤抗原的靶细胞，同时避免攻击其他细胞。此外，在两次回输小鼠体内后，它显著减少了90%的肿瘤结节，同时大幅提高了总生存期（76天 vs 30天）。这项工作最大限度地避免了继发性癌症和非特异性杀伤的风险，并可能开启天然肿瘤特异性T细胞疗法的革命性开端。
展开英文摘要原文
Recently the FDA conducted a risk investigation and labeled the Boxed Warning for all BCMA- and CD19-directed CAR-T cell therapy, so does it mean that the public must take risk of secondary cancer to receive cell therapy?
Here, without lentivirus and professional antigen presenting cell application, a novel tumor-specific T-cell therapy was successfully developed only by co-culturing MHC + cancer cells and Na ve-T cells under the CD28 co-stimulatory signals. These tumor-specific T-cells could be separated through cell size and abundantly produced from peripheral blood, and would spontaneously attack target cells that carrying the same tumor antigen while avoiding others in vitro test.
Moreover, it markedly decreased 90% tumor nodules companying with greatly improving overall survival (76 days vs 30 days) after twice infusion back to mice. This work maximally avoided the risks of secondary cancer and non-specific killing, and might open a revolutionary beginning of natural tumor-specific T-cell therapy.
论文信息
- 作者
- Dai Z、Liu XM、Zhao YL、Zhao LX、Luo XD
- 第一作者单位
- Yunnan Characteristic Plant Extraction Laboratory, Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education, Yunnan Key Laboratory of Research and Development for Natural Products, School of Pharmacy, School of Chemical Science and Technology, Yunnan University, Kunming, 650500, People's Republic of China. daizhi@ynu.edu.cn.China
- 通讯作者单位
- Yunnan Characteristic Plant Extraction Laboratory, Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education, Yunnan Key Laboratory of Research and Development for Natural Products, School of Pharmacy, School of Chemical Science and Technology, Yunnan University, Kunming, 650500, People's Republic of China. xdluo@ynu.edu.cn.China
- 期刊
- Natural products and bioprospecting2024 Aug 19
- 原文标识
- PubMed 39158647 · DOI 10.1007/s13659-024-00472-w
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →